Saquinavir Mesylate
Spécifications
149845-06-7Numéro CAS
(2S)-N-[(2S,3R)-4-[(3S,4aS,8aS)-3-(tert-butylcarbamoyl)-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinolin-2-yl]-3-hydroxy-1-phenylbutan-2-yl]-2-(quinoline-2-carbonylamino)butanediamide;methanesulfonic acidNom IUPAC
C39H54N6O8SFormule chimique
766.9 g/molMasse molaire
Saquinavir mesylate; 149845-06-7; Ro 31-8959/003; DTXSID9023835; Saquinavir monomethanesulfonate salt; UNII-UHB9Z3841A; Saquinavir methanesulfonate salt; UHB9Z3841A; Ro-31-8959/003; Ro-318959003; DTXCID803835; Saquinavir mesylate [USAN:USP]; Butanediamide, N1-((1S,2R)-3-((3S,4aS,8aS)-3-(((1,1-dimethylethyl)amino)carbonyl)octahydro-2(1H)-isoquinolinyl)-2-hydroxy-1-(phenylmethyl)propyl)-2-((2-quinolinylcarbonyl)amino)-, (2S)-, monomethanesulfonate (salt); Saquinavir mesylate (USAN:USP); SAQUINAVIR MESILATE (MART.); SAQUINAVIR MESILATE [MART.]; SAQUINAVIR MESYLATE (USP-RS); SAQUINAVIR MESYLATE [USP-RS]; SAQUINAVIR MESILATE (EP MONOGRAPH); SAQUINAVIR MESILATE [EP MONOGRAPH]; SAQUINAVIR MESYLATE (USP IMPURITY); SAQUINAVIR MESYLATE [USP IMPURITY]; SAQUINAVIR MESYLATE (USP MONOGRAPH); SAQUINAVIR MESYLATE [USP MONOGRAPH]; SQV; RefChem:57421; (S)-N-((alphaS)-alpha-((1R)-2-((3S,4AS,8AS)-3-(TERT-BUTYLCARBAMOYL)OCTAHYDRO-2(1H)-ISOQUINOLYL)-1-HYDROXYETHYL)PHENETHYL)-2-QUINALDAMIDOSUCCINAMIDE MONOMETHANESULFONATE; (S)-N-((alphaS)-alpha-((1R)-2-((3S,4AS,8AS)-3-(TERT-BUTYLCARBAMOYL)OCTAHYDRO-2(1H)-ISOQUINOLYL)-1-HYDROXYETHYL)PHENETHYL)-2-QUINALDAMIDOSUCCINAMIDE MONOMETHANESULPHONATE; BUTANEDIAMIDE, N(SUP 1)-(3-(3-(((1,1-DIMETHYLETHYL)AMINO)CARBONYL)OCTAHYDRO-2(1H)-ISOQUINOLINYL)-2-HYDROXY-1-(PHENYLMETHYL)PROPYL)-2-((2-QUINOLINYLCARBONYL)AMINO)-, (3S-(2(1R*(R*),2S*),3alpha,4Abeta,8Abeta))-, MONOMETHANESULFONATE; BUTANEDIAMIDE, N(SUP 1)-(3-(3-(((1,1-DIMETHYLETHYL)AMINO)CARBONYL)OCTAHYDRO-2(1H)-ISOQUINOLINYL)-2-HYDROXY-1-(PHENYLMETHYL)PROPYL)-2-((2-QUINOLINYLCARBONYL)AMINO)-, (3S-(2(1R*(R*),2S*),3alpha,4Abeta,8Abeta))-, MONOMETHANESULPHONATE; Invirase; Saquinavir mesilate; (S)-N1-((2S,3R)-4-((3S,4aS,8aS)-3-(tert-butylcarbamoyl)octahydroisoquinolin-2(1H)-yl)-3-hydroxy-1-phenylbutan-2-yl)-2-(quinoline-2-carboxamido)succinamide methanesulfonate; (2S)-N-[(2S,3R)-4-[(3S,4aS,8aS)-3-(tert-butylcarbamoyl)-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinolin-2-yl]-3-hydroxy-1-phenylbutan-2-yl]-2-(quinoline-2-carbonylamino)butanediamide;methanesulfonic acid; Butanediamide, N1-[(1S,2R)-3-[(3S,4aS,8aS)-3-[[(1,1-dimethylethyl)amino]carbonyl]octahydro-2(1H)-isoquinolinyl]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)-, methanesulfonate (1:1); NCGC00091469-01; MFCD00944907; Saquinavir mesilate (JAN); SAQUINAVIR MESILATE [JAN]; Saquinavir mesylate [USAN]; C39H54N6O8S; Invirase (TN); Saquinavir Mesylate?; CAS-149845-06-7; Saquinavir mesylate (AIDS Initiative); Saquinavir mesilate RS; Saquinavir mesilate CRS; Saquinavir mesylate (USP); SCHEMBL42352; (S)-N-((alphaS)-alpha-((1R)-2-((3S,4aS,8aS)-3-(tert-Butylcarbamoyl)octahydro-2(1H)-isoquinolyl)-1-hydroxyethyl)phenethyl)-2-quinaldamidosuccinamide monomethanesulfonate (salt); MLS001401395; CHEMBL282042; SCHEMBL29362141; SCHEMBL29403886; CHEBI:32121; Saquinavir (mesylate) (Standard); GLXC-02559; HMS1571O10; HMS2051D04; HMS2098O10; HMS2231C15; HMS3715O10; SAQUINAVIR MESYLATE [VANDF]; Tox21_111137; Tox21_202533; HY-17003R; SAQUINAVIR MESILATE [WHO-DD]; SAQUINAVIR MESILATE [WHO-IP]; Saquinavir for system suitability CRS; AKOS015962362; AC-1333; CCG-100992; EBC-102160; FS27793; KS-1110; NC00242; Saquinavir mesylate - Bio-X trade mark; NCGC00260082-01; SAQUINAVIR MESYLATE [ORANGE BOOK]; BS164392; Butanediamide, N(sup 1)-(3-(3-(((1,1-dimethylethyl)amino)carbonyl)octahydro-2(1H)-isoquinolinyl)-2-hydroxy-1-(phenylmethyl)propyl)-2-((2-quinolinylcarbonyl)amino)-, (3S-(2(1R*(R*),2S*),3alpha,4abeta,8abeta))-, monomethanesulfonate (salt); R-56; SMR000469290; SAQUINAVIR METHANESULFONATE SALT [MI]; Ro-31-8959-003; Saquinavir mesylate, >=98% (HPLC), powder; A12071; D01160; F84902; SR-01000763454; SR-01000763454-4; Q27114794; Saquinavir mesilate, European Pharmacopoeia (EP) Reference Standard; Saquinavir mesylate, United States Pharmacopeia (USP) Reference Standard; Saquinavir for system suitability, European Pharmacopoeia (EP) Reference Standard; (2S)-N-[(1S,2R)-3-[(3S,4aS,8aS)-3-(tert-butylcarbamoyl)-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinolin-2-yl]-1-benzyl-2-hydroxy-propyl]-2-(quinoline-2-carbonylamino)butanediamide;methanesulfonic acid; (2S)-N-[(2S,3R)-4-[(3S,4aS,8aS)-3-(tert-butylcarbamoyl)-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinolin-2-yl]-3-hydroxy-1-phenylbutan-2-yl]-2-(quinoline-2-carbonylamino)butanediamide methanesulfonate; (S)-N-((.ALPHA.S)-.ALPHA.-((1R)-2-((3S,4AS,8AS)-3-(TERT-BUTYLCARBAMOYL)OCTAHYDRO-2(1H)-ISOQUINOLYL)-1-HYDROXYETHYL)PHENETHYL)-2-QUINALDAMIDOSUCCINAMIDE MONOMETHANESULFONATE; (S)-N-((.ALPHA.S)-.ALPHA.-((1R)-2-((3S,4AS,8AS)-3-(TERT-BUTYLCARBAMOYL)OCTAHYDRO-2(1H)-ISOQUINOLYL)-1-HYDROXYETHYL)PHENETHYL)-2-QUINALDAMIDOSUCCINAMIDE MONOMETHANESULPHONATE; BUTANEDIAMIDE, N(SUP 1)-(3-(3-(((1,1-DIMETHYLETHYL)AMINO)CARBONYL)OCTAHYDRO-2(1H)-ISOQUINOLINYL)-2-HYDROXY-1-(PHENYLMETHYL)PROPYL)-2-((2-QUINOLINYLCARBONYL)AMINO)-, (3S-(2(1R*(R*),2S*),3.ALPHA.,4A.BETA.,8A.BETA.))-, MONOMETHANESULFONATE; BUTANEDIAMIDE, N(SUP 1)-(3-(3-(((1,1-DIMETHYLETHYL)AMINO)CARBONYL)OCTAHYDRO-2(1H)-ISOQUINOLINYL)-2-HYDROXY-1-(PHENYLMETHYL)PROPYL)-2-((2-QUINOLINYLCARBONYL)AMINO)-, (3S-(2(1R*(R*),2S*),3.ALPHA.,4A.BETA.,8A.BETA.))-, MONOMETHANESULPHONATE; Methanesulfonic acid--N~1~-{(2S,3R)-4-[(3S,4aS,8aS)-3-(tert-butylcarbamoyl)octahydroisoquinolin-2(1H)-yl]-3-hydroxy-1-phenylbutan-2-yl}-N~2~-(quinoline-2-carbonyl)-L-aspartamide (1/1); N-t-butyl-decahydro-2-[2(R)-hydroxy-4-phenyl-3(S)-[[N-(2-quinolylcarbonyl)-L-asparaginyl]amino]butyl]-(4aS,8aS)-isoquinoline-3(S)-carboxamide methanesulphonateSynonymes
